Branching morphogenesis and antiangiogenesis candidates: Tip cells lead the way

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 315-326

  Carmeliet, Peter ^a   De Smet, Frederik ^a   Loges, Sonja ^a   Mazzone, Massimiliano ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MK 0752; NEUROPILIN INHIBITOR; NOTCH RECEPTOR; PLACENTAL GROWTH FACTOR ANTIBODY; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN 2 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR 3 INHIBITOR; WNT PROTEIN; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; BRANCHING MORPHOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SURVIVAL TIME; TUMOR VASCULARIZATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MORPHOGENESIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; STROMA CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; MORPHOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68549085490     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.64     Document Type: Review

References (89)

1. Affolter, M. & Caussinus, E. Tracheal branching morphogenesis in Drosophila: New insights into cell behavior and organ architecture. Development 135, 2055-2064 (2008).
2. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177 (2003).
3. Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684-2698 (2002).
4. Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009).
5. Jain, R. K. Normalization of tumor vasculature: An emerging concept in anti-angiogenic therapy. Science 307, 58-62 (2005).
6. Crawford, Y. & Ferrara, N. VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res. 335, 261-269 (2009).
7. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: Mechanisms of anti-tumor activity. Nat. Rev. Cancer 8, 579-591 (2008).
8. Stalmans, I. et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109, 327-336 (2002).
9. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007).
10. Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716 (2003).
11. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
12. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 435-439 (1996).
13. Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 102-111 (2005).
14. Potenta, S., Zeisberg, E. & Kalluri, R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 99, 1375-1379 (2008).
15. Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813 (2008).
16. Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
17. Paez-Ribes, M. et al. Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
18. Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006).
19. Ridgway, J. et al. Inhibition of Dll4 signaling inhibits tumor growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006).
20. Dufraine, J., Funahashi, Y. & Kitajewski, J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27, 5132-5137 (2008).
21. Funahashi, Y. et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 68, 4727-4735 (2008).
22. D'Souza, B., Miyamoto, A. & Weinmaster, G. The many facets of Notch ligands. Oncogene 27, 5148-5167 (2008).
23. Hofmann, J. J. & Iruela-Arispe, M. L. Notch signaling in blood vessels: who is talking to whom about what? Circ. Res. 100, 1556-1568 (2007).
24. Phng, L. K. et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev. Cell 16, 70-82 (2009).
25. Hellström, M. et al. Dll4 signaling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007).
26. Suchting, S. et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl Acad. Sci. USA 104, 3225-3230 (2007).
27. Siekmann, A. F. & Lawson, N. D. Notch signaling limits angiogenic cell behavior in developing zebrafish arteries. Nature 445, 781-784 (2007).
28. Scehnet, J. S. et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109, 4753-4760 (2007).
29. Poellinger, L. & Lendahl, U. Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr. Opin. Genet. Dev. 18, 449-454 (2008).
30. Hayward, P., Kalmar, T. & Arias, A. M. Wnt/Notch signaling and information processing during development. Development 135, 411-424 (2008).
31. Tammela, T. et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660 (2008).
32. Dou, G. R. et al. RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J. 22, 1606-1617 (2008).
33. Li, J. L. et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67, 11244-11253 (2007).
34. Hu, X. B. et al. Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia 11, 32-38 (2009).
35. Koch, U. & Radtke, F. Notch and cancer: A double-edged sword. Cell. Mol. Life Sci. 64, 2746-2762 (2007).
36. Xue, Y. et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet. 8, 723-730 (1999).
37. High, F. A. et al. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc. Natl Acad. Sci. USA 105, 1955-1959 (2008).
38. Zeng, Q. et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8, 13-23 (2005).
39. Karpanen, T. & Alitalo, K. Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol. 3, 367-397 (2008).
40. Ny, A. et al. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat. Med. 11, 998-1004 (2005).
41. He, Y. et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl Cancer Inst. 94, 819-825 (2002).
42. Dumont, D. J. et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946-949 (1998).
43. shawber, C. J. et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 117, 3369-3382 (2007).
44. Haiko, P. et al. Deletion of vascular endothelial growth factor C (veGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 28, 4843-4850 (2008).
45. Caunt, M. et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13, 331-342 (2008).
46. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
47. Padera, T. P. et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7, 2272-2279 (2008).
48. Neufeld, G. & Kessler, O. The semaphorins: Versatile regulators of tumor progression and tumor angiogenesis. Nat. Rev. Cancer 8, 632-645 (2008).
49. Bielenberg, D. R., Pettaway, C. A., Takashima, S. & Klagsbrun, M. Neuropilins in neoplasms: Expression, regulation, and function. Exp. Cell. Res. 312, 584-593 (2006).
50. Vieira, J. M., Schwarz, Q. & Ruhrberg, C. Selective requirements for NRP1 ligands during neurovascular patterning. Development 134 1833-1843 (2007).
51. Wang, L. et al. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS ONE 2, e1161 (2007).
52. Chittenden, T. W. et al. Selective regulation of arterial branching morphogenesis by synectin. Dev. Cell 10, 783-795 (2006).
53. Eichmann, A., Le Noble, F., Autiero, M. & Carmeliet, P. Guidance of vascular and neural network formation. Curr. Opin. Neurobiol. 15, 108-115 (2005).
54. Staton, C. A., Kumar, I., Reed, M. W. & Brown, N. J. Neuropilins in physiological and pathological angiogenesis. J. Pathol. 212, 237-248 (2007).
55. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998).
56. Pan, Q. et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11 53-67 (2007).
57. Gerhardt, H. et al. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev. Dyn. 231, 503-509 (2004).
58. Miao, H. Q. et al. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 146, 233-242 (1999).
59. McLennan, R. & Kulesa, P. M. In vivo analysis reveals a critical role for neuropilin-1 in cranial neural crest cell migration in chick. Dev. Biol. 301, 227-239 (2007).
60. Siekmann, A. F., Covassin, L. & Lawson, N. D. Modulation of VEGF signaling output by the Notch pathway. Bioessays 30, 303-313 (2008).
61. Stella, M. C., Trusolino, L., Pennacchietti, S. & Comoglio, P. M. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell Biol. 25, 3982-3996 (2005).
62. Harrington, L. S. et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc. Res. 75, 144-154 (2008).
63. Matthies, A. M., Low, Q. E., Lingen, M. W. & DiPietro, L. A. Neuropilin-1 participates in wound angiogenesis. Am. J. Pathol. 160, 289-296 (2002).
64. Yuan, L. et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129, 4797-4806 (2002).
65. Shen, J. et al. Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. Mol. Med. 10, 12-18 (2004).
66. Dallas, N. A. et al. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin. Cancer Res. 14 8052-8060 (2008).
67. Autiero, M. et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9, 936-943 (2003).
68. Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8, 942-956 (2008).
69. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7 575-583 (2001).
70. Kappas, N. C. et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J. Cell Biol. 181 847-858 (2008).
71. Boulton, M. E., Cai, J. & Grant, M. B. Gamma-secretase: A multifaceted regulator of angiogenesis. J. Cell. Mol. Med. 12, 781-795 (2008).
72. Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840 (2002).
73. Kaplan, R. N. et al. VEGFR1-positive hematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
74. Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007).
75. Taylor, A. P., Rodriguez, M., Adams, K., Goldenberg, D. M. & Blumenthal, R. D. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: Potential relationship to post-therapy tumor angiogenesis and recurrence. Int. J. Cancer 105, 158-164 (2003).
76. Kaelin, W. G., Jr & Ratcliffe, P. J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol. Cell 30, 393-402 (2008).
77. Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394, 485-490 (1998).
78. Wu, S. et al. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol. Ther. 16, 1227-1234 (2008).
79. Nangaku, M. et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler. Thromb. Vasc. Biol. 27, 2548-2554 (2007).
80. Dor, Y. et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21, 1939-1947 (2002).
81. Nasarre, P. et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 69, 1324-1333 (2009).
82. Kashiwagi, S. et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14, 255-257 (2008).
83. Jones, C. A. et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat. Med. 14, 448-453 (2008).
84. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumors promotes immune destruction. Nature 453, 410-414 (2008).
85. Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 814-818 (2008).
86. Chen, J. X. & Stinnett, A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 57, 3335-3343 (2008).
87. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 553-563 (2004).
88. Kerbel, R. S. Anti-angiogenic therapy: A universal chemosensitization strategy for cancer? Science 312, 1171-1175 (2006).
89. Sullivan, C. J., Doetschman, T. & Hoying, J. B. Targeted disruption of the Fgf2 gene does not affect vascular growth in the mouse ischemic hindlimb. J. Appl. Physiol. 93, 2009-2017 (2002).